Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* 18 years of age or greater~* must be scheduled for an autologous or allogeneic bone marrow or peripheral stem cell transplant~* Eastern Cooperative Oncology Group(ECOG) performance status \< or = 2~* patients must have signed informed consent~* must be able to swallow tablets and capsules~* must be receiving a cyclophosphamide containing regimen.~Exclusion:~* patient has known sensitivity to aprepitant, ondansetron, or dexamethasone~* patient has received another investigational drug in the past 30 days~* patient has had emesis or requires antiemetic agents in the 48 hours prior to beginning conditioning therapy~* patient has taken neurokinin-1 antagonists for 14 days prior to enrollment~* patient is pregnant, has a positive serum human chorionic gonadotropin(hCg) or is lactating~* patient has serum creatinine level \> or = 2\*ULN~* patient has severe hepatic insufficiency (Child-Pugh score \>9)~* patient drinks \> 5 drinks/day for the last year~* patient with concurrent illness requiring systemic corticosteroid use other than planned dexamethasone during conditioning therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: ACTIVE_COMPARATOR): None
- sugar pill (Type: PLACEBO_COMPARATOR): Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).